Sorafenib is the first drug approved to treat advanced hepatocellular carcinoma (HCC) and
continues as the gold-standard therapy against HCC. However, acquired drug resistance …

Abstract Sorafenib (Nexavar, BAY43‑9006 or Sora) is the first molecular targeted agent that
has exhibited significant therapeutic benefits in advanced hepatocellular carcinoma (HCC) …

abstract Hepatocellular carcinoma (HCC) is the most common primary liver tumor (PLT), with
cholangiocarcinoma (CC) being the second most frequent. Glucose transporter 1 (GLUT-1) …

Abstract Capsaicin (8‑methyl N‑vanillyl‑6 nonenamide) is a natural plant extract that has
antitumor properties and induces apoptosis and autophagy in various types of malignancies …

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular
carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the …

Quercetin is a flavonoid present in fruits, vegetables and plants with antioxidant, anti-
inflammatory and anticancer properties. Its beneficial activities have been demonstrated in …

This study investigated the therapeutic effects of the phytochemical crocin alone or in
combination with sorafenib both in rats chemically induced with hepatocellular carcinoma …

Background Sorafenib, a multiple-target-point kinase inhibitor, has been used as a standard
treatment for advanced liver cancer and has shown therapeutic benefits. However …

Objective Hepatocellular carcinima is one of the most common tumors in clinic and also one
of the leading causes of death from cancer worldwide. Quercetin shows significant effects on …

Hepatocellular carcinoma (HCC) is one of the most common cancers and lethal diseases in
the world. Although the majority of HCC cases occur in developing countries of Asia and …